IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 33 filers reported holding IMPEL NEUROPHARMA INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $80,391 | -9.3% | 63,300 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $88,620 | -29.0% | 63,300 | +90.1% | 0.00% | -33.3% |
| Q4 2022 | $124,875 | -62.5% | 33,300 | -51.2% | 0.00% | -66.7% |
| Q3 2022 | $333,000 | -54.4% | 68,300 | -12.8% | 0.01% | -47.1% |
| Q2 2022 | $730,000 | +46.3% | 78,300 | 0.0% | 0.02% | +70.0% |
| Q1 2022 | $499,000 | -26.2% | 78,300 | 0.0% | 0.01% | -23.1% |
| Q4 2021 | $676,000 | – | 78,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| 5AM Venture Management, LLC | 2,884,791 | $24,896,000 | 4.67% |
| venBio Partners LLC | 2,759,791 | $23,817,000 | 4.29% |
| Vivo Capital, LLC | 2,884,789 | $24,896,000 | 1.50% |
| LASRY MARC | 330,000 | $2,848,000 | 1.41% |
| DCF Advisers, LLC | 256,027 | $2,210,000 | 0.90% |
| Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $35,693,000 | 0.20% |
| EPIQ PARTNERS, LLC | 18,646 | $161,000 | 0.09% |
| Anson Funds Management LP | 17,729 | $153,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 78,300 | $676,000 | 0.01% |
| TRUSTCORE FINANCIAL SERVICES, LLC | 13,407 | $116,000 | 0.01% |